Showing 2261-2270 of 5909 results for "".
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Pantheon Vision Announces Partnership with EyeDeal Medical to Develop Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-announces-partnership-with-eyedeal-medical-to-develop-bioengineered-corneal-implant/2482719/Pantheon Vision today announced a partnership with manufacturer EyeDeal Medical to develop an artificial, bioengineered corneal implant. Their goal, the company states, is to eliminate corneal blindness by removing the need for human donor corneal tissue. Corneal blindness is the
- Staar Surgical Announces Restructure of Leadershiphttps://modernod.com/news/staar-surgical-announces-restructure-of-leadership/2482705/Staar Surgical announced a series of changes to their leadership structure. These changes come in an effort to better address marketing needs, according to Staar. Warren Foust, Chief Operating Officer, has been promoted to the newly created role of Preside
- Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Developmenthttps://modernod.com/news/harrow-secures-5-year-strategic-agreement-for-triesence-and-announces-next-generation-development/2482696/Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid is FDA-approved for visualization during vitrectomy
- Nicox Announces New Data from the NCX 470 Mont Blanc Trial, Provides Development Updateshttps://modernod.com/news/nicox-announces-new-data-from-the-ncx-470-mont-blanc-trial-provides-development-updates/2482684/Nicox, an international ophthalmology company, shared new data on their intraocular pressure (IOP)-lowering medication NCX 470 at the 2025 American Glaucoma Society (AGS) Annual Meeting this past weekend. The French company also shared developmental updates from the 470 Mont Blanc phase 3 clinica
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op
- Multifocal Contact Lens in Children Slows Myopia Progression with Lasting Effects, NIH Studyhttps://modernod.com/news/multifocal-contact-lens-in-children-slows-myopia-progression-with-lasting-effects-nih-study/2482643/A new NIH-funded study cites that children who wear multifocal contact lenses to slow progression of myopia maintain their benefits even after they stop wearing contacts as teenagers. This study was a follow-up to the BLINK trial,
- Study Demonstrates Efficacy of AI in Enabling Home OCT Monitoringhttps://modernod.com/news/study-demonstrates-efficacy-of-ai-in-enabling-home-oct-monitoring/2482641/Notal Vision announced the publication of pivotal study results evaluating the performance of its artificial intelligence (AI) algorithm designed to estimate key biomarkers in wet age-
- Surgilūm's RoboMarker G2 Receives 5 International Medical Device Design Awardshttps://modernod.com/news/surgilums-robomarker-g2-receives-5-international-medical-device-design-awards/2482638/Surgilūm's RoboMarker G2 was awarded international medical device design awards by 3 associations. The awards include: New York Product Design Award: an international competition celebrating excellence in product desi